Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms.
about
Treatment of Bullous Systemic Lupus ErythematosusIntense pulsed light treatment for chronic facial erythema of systemic lupus erythematosus: a case report.Update on the management of cutaneous lupus erythematosus.Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation.Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.Adalimumab-induced lupus serositis.Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.Treatment of cutaneous lupus.Cutaneous lupus erythematosus: a personal approach to management.The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications.A comparison of vitamin A and leucovorin for the prevention of methotrexate-induced micronuclei production in rat bone marrowLupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects.Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.The use of methotrexate in dermatology: a review.The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies--a systematic review.Antitumor and immunomodulatory effects of low-dose 5-FU on hepatoma 22 tumor-bearing miceTherapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children.Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
P2860
Q28087628-8D622D17-F292-43AF-9D89-B87BB6AAEF53Q30989243-0ABABCF9-BADB-4491-A5E3-0E26C06A4B88Q31121574-295CFF21-F34D-4254-99BF-11B2787DCC07Q33411063-EC05F0F0-7F2B-4EB1-A3FC-4C9908F70483Q34548422-404B2E5C-23A0-4917-A362-9AEE0F68A2D9Q35203953-FC7F99C4-4956-4928-9820-2FCE123C6AD9Q35555309-8A257653-DBAD-4D2E-90E5-336822887C48Q35633324-F6637431-39BD-4955-AA2C-4F1DEBDDE60FQ36365400-FC13DA9A-C415-4C0F-9D38-B636F024CF52Q36373315-3FF35067-6284-4B97-B2E8-B0E0824E4FE2Q37147562-EDCD43D9-243B-4899-AA67-6878E1D1D780Q37609869-BA16DE11-655C-4FBE-B627-C898D40505D5Q37728232-1B5D07DA-5F31-4C39-8879-905F88E89A0FQ37867162-E9C5FCD7-D258-46F4-8CD5-EB1CCBE862DAQ37981730-5FE84A24-8DFF-4107-813E-3BDA7ECB105BQ38357969-0952A2FE-EAD2-4083-88D4-3269B57C86ACQ38374526-752422BC-2D2E-4F40-BC6B-2B19B22D8B42Q38850089-5CD6533D-8ADF-4B78-8159-20A6620781AEQ38857518-7A92DB47-A656-4C96-A221-A48BE4D3FCFAQ40590985-5D768C07-C71C-4DE6-89BF-B6D22B9446F6Q46890990-074442CF-9594-47ED-84FA-22AFB81C1B4BQ53845804-767AA731-AF43-4F9E-A68F-659D14D52FAF
P2860
Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Management of cutaneous lupus ...... on of inflammatory mechanisms.
@ast
Management of cutaneous lupus ...... on of inflammatory mechanisms.
@en
Management of cutaneous lupus ...... on of inflammatory mechanisms.
@nl
type
label
Management of cutaneous lupus ...... on of inflammatory mechanisms.
@ast
Management of cutaneous lupus ...... on of inflammatory mechanisms.
@en
Management of cutaneous lupus ...... on of inflammatory mechanisms.
@nl
prefLabel
Management of cutaneous lupus ...... on of inflammatory mechanisms.
@ast
Management of cutaneous lupus ...... on of inflammatory mechanisms.
@en
Management of cutaneous lupus ...... on of inflammatory mechanisms.
@nl
P2093
P356
P1476
Management of cutaneous lupus ...... on of inflammatory mechanisms.
@en
P2093
P2888
P356
10.1007/S002960050058
P577
1998-01-01T00:00:00Z
P6179
1022602708